http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3834203-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9031fd30f160bc41a09ebad87d8d7648 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H10-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H70-60 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H10-20 |
| filingDate | 2019-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed5fa4c310666099bdbe47392b751c55 |
| publicationDate | 2021-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3834203-A1 |
| titleOfInvention | Method and system for developing clinical trial protocols |
| abstract | The present invention discloses methods and systems for developing clinical trial protocols, in particular, the inclusion/exclusion criteria used to define targeted patient population. In some embodiments, the present invention provides methods and systems to develop and/or optimize the inclusion/exclusion criteria based on quantitative analysis. In some embodiments, the methods and systems of the present invention allow to achieve the objectives of a clinical trial. |
| priorityDate | 2018-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419588349 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280352 |
Total number of triples: 16.